Bionime Corporation (4737.TW)
TWD 66.0
(-0.9%)
TWD 66.0
(-0.9%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 1.75 Billion TWD | -20.58% |
| 2022 | 2.21 Billion TWD | 19.5% |
| 2021 | 1.84 Billion TWD | 10.87% |
| 2020 | 1.66 Billion TWD | -23.21% |
| 2019 | 2.17 Billion TWD | 8.26% |
| 2018 | 2 Billion TWD | 10.27% |
| 2017 | 1.82 Billion TWD | 4.59% |
| 2016 | 1.74 Billion TWD | 8.11% |
| 2015 | 1.6 Billion TWD | 5.58% |
| 2014 | 1.52 Billion TWD | -2.32% |
| 2013 | 1.56 Billion TWD | 8.77% |
| 2012 | 1.43 Billion TWD | -2.81% |
| 2011 | 1.47 Billion TWD | 21.85% |
| 2010 | 1.21 Billion TWD | 29.22% |
| 2009 | 937.75 Million TWD | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q2 | 474.78 Million TWD | 1.35% |
| 2024 Q1 | 468.47 Million TWD | -4.33% |
| 2023 Q3 | 425.14 Million TWD | -0.12% |
| 2023 FY | 1.75 Billion TWD | -20.58% |
| 2023 Q1 | 415.12 Million TWD | -30.44% |
| 2023 Q4 | 489.65 Million TWD | 15.17% |
| 2023 Q2 | 425.64 Million TWD | 2.53% |
| 2022 Q2 | 573.32 Million TWD | 20.54% |
| 2022 FY | 2.21 Billion TWD | 19.5% |
| 2022 Q1 | 475.64 Million TWD | -0.42% |
| 2022 Q3 | 564.83 Million TWD | -1.48% |
| 2022 Q4 | 596.77 Million TWD | 5.65% |
| 2021 Q4 | 477.66 Million TWD | -3.67% |
| 2021 FY | 1.84 Billion TWD | 10.87% |
| 2021 Q1 | 463.79 Million TWD | -8.55% |
| 2021 Q2 | 412.58 Million TWD | -11.04% |
| 2021 Q3 | 495.87 Million TWD | 20.19% |
| 2020 Q1 | 353.4 Million TWD | -52.97% |
| 2020 Q2 | 359.41 Million TWD | 1.7% |
| 2020 Q3 | 448.61 Million TWD | 24.82% |
| 2020 FY | 1.66 Billion TWD | -23.21% |
| 2020 Q4 | 507.15 Million TWD | 13.05% |
| 2019 FY | 2.17 Billion TWD | 8.26% |
| 2019 Q1 | 364.19 Million TWD | -41.45% |
| 2019 Q2 | 570.78 Million TWD | 56.73% |
| 2019 Q3 | 486.51 Million TWD | -14.76% |
| 2019 Q4 | 751.43 Million TWD | 54.45% |
| 2018 FY | 2 Billion TWD | 10.27% |
| 2018 Q4 | 621.98 Million TWD | 11.87% |
| 2018 Q3 | 555.99 Million TWD | 25.33% |
| 2018 Q2 | 443.61 Million TWD | 15.03% |
| 2018 Q1 | 385.63 Million TWD | -33.08% |
| 2017 Q4 | 576.26 Million TWD | 31.98% |
| 2017 Q3 | 436.61 Million TWD | 3.47% |
| 2017 FY | 1.82 Billion TWD | 4.59% |
| 2017 Q2 | 421.98 Million TWD | 9.49% |
| 2017 Q1 | 385.39 Million TWD | -26.82% |
| 2016 FY | 1.74 Billion TWD | 8.11% |
| 2016 Q4 | 526.65 Million TWD | 18.16% |
| 2016 Q3 | 445.7 Million TWD | 2.99% |
| 2016 Q2 | 432.75 Million TWD | 29.11% |
| 2016 Q1 | 335.19 Million TWD | -23.94% |
| 2015 FY | 1.6 Billion TWD | 5.58% |
| 2015 Q3 | 428.17 Million TWD | 16.76% |
| 2015 Q4 | 440.68 Million TWD | 2.92% |
| 2015 Q2 | 366.72 Million TWD | -1.98% |
| 2015 Q1 | 374.12 Million TWD | -19.53% |
| 2014 Q4 | 464.91 Million TWD | 20.62% |
| 2014 Q1 | 328.25 Million TWD | -15.08% |
| 2014 Q2 | 346.05 Million TWD | 5.42% |
| 2014 FY | 1.52 Billion TWD | -2.32% |
| 2014 Q3 | 385.43 Million TWD | 11.38% |
| 2013 Q3 | 397.91 Million TWD | -6.07% |
| 2013 Q1 | 352.8 Million TWD | 6.1% |
| 2013 FY | 1.56 Billion TWD | 8.77% |
| 2013 Q4 | 386.55 Million TWD | -2.86% |
| 2013 Q2 | 423.61 Million TWD | 20.07% |
| 2012 Q1 | 325.4 Million TWD | -23.81% |
| 2012 Q4 | 332.5 Million TWD | -14.76% |
| 2012 Q3 | 390.08 Million TWD | 2.45% |
| 2012 Q2 | 380.74 Million TWD | 17.01% |
| 2012 FY | 1.43 Billion TWD | -2.81% |
| 2011 Q1 | 308.55 Million TWD | -14.47% |
| 2011 FY | 1.47 Billion TWD | 21.85% |
| 2011 Q4 | 427.09 Million TWD | 12.71% |
| 2011 Q3 | 378.92 Million TWD | 4.68% |
| 2011 Q2 | 361.97 Million TWD | 17.31% |
| 2010 Q4 | 360.75 Million TWD | 18.06% |
| 2010 Q2 | 293.99 Million TWD | 16.93% |
| 2010 Q3 | 305.57 Million TWD | 3.94% |
| 2010 Q1 | 251.42 Million TWD | 0.0% |
| 2010 FY | 1.21 Billion TWD | 29.22% |
| 2009 FY | 937.75 Million TWD | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| Nang Kuang Pharmaceutical Co., Ltd. | 2.15 Billion TWD | 18.354% |
| Maxigen Biotech Inc. | 622.11 Million TWD | -182.193% |
| SciVision Biotech Inc. | 712.98 Million TWD | -146.227% |
| Pegavision Corporation | 6.78 Billion TWD | 74.144% |
| Visco Vision Inc. | 2.39 Billion TWD | 26.78% |